A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

Barry Paul; Michaela Liedtke; Jack Khouri; Robert Rifkin; Mitul D. Gandhi; Andrew Kin; Moshe Y. Levy; Rebecca Silbermann; Francesca Cottini; Douglas W. Sborov; Irwindeep Sandhu; Lyssa Villarreal; Michael Murphy; Lin Gu; Ann Chen; Nishanthan Rajakumaraswamy; Saad Z. Usmani

doi:10.2217/fon-2022-0975

A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

Barry Paul, Michaela Liedtke, Jack Khouri, Robert Rifkin, Mitul D. Gandhi, Andrew Kin, Moshe Y. Levy, Rebecca Silbermann, Francesca Cottini, Douglas W. Sborov, Irwindeep Sandhu, Lyssa Villarreal, Michael Murphy, Lin Gu, Ann Chen, Nishanthan Rajakumaraswamy, Saad Z. Usmani

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Magrolimab is a monoclonal antibody that blocks CD47, a ‘do not eat me' signal overexpressed on tumor cells. CD47 is overexpressed in multiple myeloma (MM), which contributes to its pathogenesis. Preclinical studies have shown that CD47 blockade induces macrophage activation, resulting in elimination of myeloma cells, and that there is synergy between magrolimab and certain anticancer therapies. These findings suggest that magrolimab-based combinations may have a therapeutic benefit in MM. This phase II study investigates magrolimab in combination with commonly used myeloma therapies in patients with relapsed/refractory MM and includes a safety run-in phase followed by a dose-expansion phase. Primary end points include the incidence of dose-limiting toxicities and adverse events (safety run-in) and the objective response rate (dose expansion).

Original language	English (US)
Pages (from-to)	7-17
Number of pages	11
Journal	Future Oncology
Volume	19
Issue number	1
DOIs	https://doi.org/10.2217/fon-2022-0975
State	Published - Jan 1 2023

Keywords

CD47
bortezomib
carfilzomib
daratumumab
dexamethasone
immunotherapy
magrolimab
multiple myeloma
pomalidomide

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2022-0975

Cite this

Paul, B., Liedtke, M., Khouri, J., Rifkin, R., Gandhi, M. D., Kin, A., Levy, M. Y., Silbermann, R., Cottini, F., Sborov, D. W., Sandhu, I., Villarreal, L., Murphy, M., Gu, L., Chen, A., Rajakumaraswamy, N., & Usmani, S. Z. (2023). A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma. Future Oncology, 19(1), 7-17. https://doi.org/10.2217/fon-2022-0975

Paul, B, Liedtke, M, Khouri, J, Rifkin, R, Gandhi, MD, Kin, A, Levy, MY, Silbermann, R, Cottini, F, Sborov, DW, Sandhu, I, Villarreal, L, Murphy, M, Gu, L, Chen, A, Rajakumaraswamy, N & Usmani, SZ 2023, 'A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma', Future Oncology, vol. 19, no. 1, pp. 7-17. https://doi.org/10.2217/fon-2022-0975

@article{0a291acc6ae54954a95dc3c40a39ae97,

title = "A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma",

abstract = "Magrolimab is a monoclonal antibody that blocks CD47, a {\textquoteleft}do not eat me' signal overexpressed on tumor cells. CD47 is overexpressed in multiple myeloma (MM), which contributes to its pathogenesis. Preclinical studies have shown that CD47 blockade induces macrophage activation, resulting in elimination of myeloma cells, and that there is synergy between magrolimab and certain anticancer therapies. These findings suggest that magrolimab-based combinations may have a therapeutic benefit in MM. This phase II study investigates magrolimab in combination with commonly used myeloma therapies in patients with relapsed/refractory MM and includes a safety run-in phase followed by a dose-expansion phase. Primary end points include the incidence of dose-limiting toxicities and adverse events (safety run-in) and the objective response rate (dose expansion).",

keywords = "CD47, bortezomib, carfilzomib, daratumumab, dexamethasone, immunotherapy, magrolimab, multiple myeloma, pomalidomide",

author = "Barry Paul and Michaela Liedtke and Jack Khouri and Robert Rifkin and Gandhi, {Mitul D.} and Andrew Kin and Levy, {Moshe Y.} and Rebecca Silbermann and Francesca Cottini and Sborov, {Douglas W.} and Irwindeep Sandhu and Lyssa Villarreal and Michael Murphy and Lin Gu and Ann Chen and Nishanthan Rajakumaraswamy and Usmani, {Saad Z.}",

note = "Publisher Copyright: {\textcopyright} 2023 Gilead Sciences, Inc.",

year = "2023",

month = jan,

day = "1",

doi = "10.2217/fon-2022-0975",

language = "English (US)",

volume = "19",

pages = "7--17",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "1",

}

TY - JOUR

T1 - A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

AU - Paul, Barry

AU - Liedtke, Michaela

AU - Khouri, Jack

AU - Rifkin, Robert

AU - Gandhi, Mitul D.

AU - Kin, Andrew

AU - Levy, Moshe Y.

AU - Silbermann, Rebecca

AU - Cottini, Francesca

AU - Sborov, Douglas W.

AU - Sandhu, Irwindeep

AU - Villarreal, Lyssa

AU - Murphy, Michael

AU - Gu, Lin

AU - Chen, Ann

AU - Rajakumaraswamy, Nishanthan

AU - Usmani, Saad Z.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Magrolimab is a monoclonal antibody that blocks CD47, a ‘do not eat me' signal overexpressed on tumor cells. CD47 is overexpressed in multiple myeloma (MM), which contributes to its pathogenesis. Preclinical studies have shown that CD47 blockade induces macrophage activation, resulting in elimination of myeloma cells, and that there is synergy between magrolimab and certain anticancer therapies. These findings suggest that magrolimab-based combinations may have a therapeutic benefit in MM. This phase II study investigates magrolimab in combination with commonly used myeloma therapies in patients with relapsed/refractory MM and includes a safety run-in phase followed by a dose-expansion phase. Primary end points include the incidence of dose-limiting toxicities and adverse events (safety run-in) and the objective response rate (dose expansion).

AB - Magrolimab is a monoclonal antibody that blocks CD47, a ‘do not eat me' signal overexpressed on tumor cells. CD47 is overexpressed in multiple myeloma (MM), which contributes to its pathogenesis. Preclinical studies have shown that CD47 blockade induces macrophage activation, resulting in elimination of myeloma cells, and that there is synergy between magrolimab and certain anticancer therapies. These findings suggest that magrolimab-based combinations may have a therapeutic benefit in MM. This phase II study investigates magrolimab in combination with commonly used myeloma therapies in patients with relapsed/refractory MM and includes a safety run-in phase followed by a dose-expansion phase. Primary end points include the incidence of dose-limiting toxicities and adverse events (safety run-in) and the objective response rate (dose expansion).

KW - CD47

KW - bortezomib

KW - carfilzomib

KW - daratumumab

KW - dexamethasone

KW - immunotherapy

KW - magrolimab

KW - multiple myeloma

KW - pomalidomide

UR - http://www.scopus.com/inward/record.url?scp=85151043976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151043976&partnerID=8YFLogxK

U2 - 10.2217/fon-2022-0975

DO - 10.2217/fon-2022-0975

M3 - Review article

C2 - 36779512

AN - SCOPUS:85151043976

SN - 1479-6694

VL - 19

SP - 7

EP - 17

JO - Future Oncology

JF - Future Oncology

IS - 1

ER -

A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this